You are here:
NICE
NICE Guidance
Conditions and diseases
Cancer
Ovarian cancer
Guidance on the use of paclitaxel in the treatment of ovarian cancer
Technology appraisal guidance
Reference number:
TA55
Published:
22 January 2003
Last updated:
01 May 2005
Guidance
Tools and resources
Information for the public
History
Download guidance (PDF)
Overview
1 Guidance
2 Clinical need and practice
3 The technology
4 Evidence
5 Implications for the NHS
6 Further research
7 Implementation
8 Related guidance
9 Review of guidance
Appendix A. Appraisal Committee members
Appendix B. Sources of evidence considered by the Committee
Appendix C. Patient information. Guidance on the use of paclitaxel in the treatment of ovarian cancer
Appendix D. Detail on criteria for audit of the use of paclitaxel in the treatment of women with ovarian cancer
Changes after publication
About this guidance
Appendix C. Patient information. Guidance on the use of paclitaxel in the treatment of ovarian cancer
A
summary for patients and carers
can be found on the NICE website.
Next page
Appendix D. Detail on criteria for audit of the use of paclitaxel in the treatment of women with ovarian cancer
Previous page
Appendix B. Sources of evidence considered by the Committee